FDA Approved: RINVOQ — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA approved AbbVie’s supplemental application for Rinvoq (upadacitinib), resulting in a labeling update for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis
• Axial Spondyloarthritis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• RINVOQ (Upadacitinib)

Snippet

SUPPL AP for RINVOQ (UPADACITINIB)